Current Clinical Trials

Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SCUSF
Indentifier #: NCT01009918
Title: SCUSF-0806, Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin)
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Indentifier #: NCT01841736
Title: Alliance A021202, Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors; ClinicalTrials.gov identifier: NCT01841736
Department: Oncology
Diagnosis: Genito-urinary - Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT00942331
Title: CALGB-90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, And Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: CTSU -NCI
Indentifier #: NCT00588770
Title: E1305, A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01274338
Title: E1609, A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-risk Melanoma
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01642251
Title: E2511, Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Department: Oncology
Diagnosis: Gastrointestinal - Liver
Principal Investigator:
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT01015833
Title: CALGB 80802, Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients with Advanced Hepatocellular Carcinoma (HCC)
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Lowry MD, Philip
Sponsor: CALGB
Indentifier #: NCT01150045
Title: CALGB 80702, A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01286272
Title: CALGB 50904, A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Indentifier #: NCT01835158
Title: Alliance A031203,Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma